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Ischemia/reperfusion (I/R) is a condition that stimulates an intense inﬂammatory response. No
ideal treatment exists. Triﬂusal is an antiplatelet salicylate derivative with anti-inﬂammatory effects.
S-adenosylmethionine is a metabolic precursor for glutathione, an endogenous antioxidant. Dex-
tromethorphan is a low-afﬁnity N-methyl-D-aspartate receptor inhibitor. There is evidence that
these agents modulate some of the pathways involved in I/R physiopathology. Intestinal I/R was
induced in rats by clamping the superior mesenteric artery for 60minutes, followed by 60minutes
of reperfusion. Rats either received saline or the drugs studied. At the end of the procedure, serum
concentrations of tumor necrosis factor-alpha (TNF-alpha), malonaldehyde (MDA), and total anti-
oxidant capacity (TAC) were determined and intestinal morphology analyzed. I/R resulted in tissue
damage, serum TNF-alpha and MDA elevations, and depletion of TAC. All drugs showed tissue
protection. Only triﬂusal reduced TNF-alpha levels. All drugs lowered MDA levels, but only triﬂusal
and S-adenosylmethionine maintained the serum TAC.
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1. INTRODUCTION
Intestinal ischemia occurs when there is an interruption of the blood supply to the intestine, or when there
is inadequate organ perfusion due to conditions of shock or hypovolemia [1]. It is also an unavoidable
condition during transplant and other surgical procedures, such as aortic repair. The initial damage caused
by ischemia is further worsened by reperfusion. This entity is known as ischemia/reperfusion (I/R) injury.
I/R can adversely affect transplant outcomes and induces a systemic life-risking inﬂammatory response.
I/R injury is mediated by multiple mechanisms such as production of reactive oxygen species,intravascular
thrombosis, inﬂammatory cell inﬁltration, and cytokine production [2]. Rodent models of intestinal I/R
are useful in order to study the physiopathological mechanisms of I/R injury as well as in the search for
much needed novel protective strategies [1]. In this study, we evaluated the value of triﬂusal (TRI), S-
adenosylmethionine (SAME), and dextromethorphan (DEX) over intestinal I/R injury. All of these agents
are currently in clinical use.
TRI is an antiplatelet drug related to but not derived from acetylsalicylic acid, that acts through
the modulation of thromboxane synthesis but also possesses neuroprotective, antioxidant, and anti-
inﬂammatory properties [3]. TRI has been shown to decrease cerebral I/R injury and to prevent ischemia-
induced cytokine expression in neural cells [4]. SAME is an amino acid that serves as a precursor to glu-
tathione,amajorphysiologicalantioxidant,andservesanimportantfunctionin opposingfree radialproduc-
tion and oxidative stress generated by various pathological processes [5]. SAME has been shown to reduce
brain and liver I/R injury, through decreasedlipid peroxidation and induction of antioxidant defenses[6, 7].
DEX is a antitussive and neuroprotective agent and a low-afﬁnity N-methyl-D-aspartate (NMDA) receptor
channelblocker. Studies have demonstrated that DEX protects the brain againstI/R injury [8]. In one recent
study, DEX was able to reduce intestinal I/R-induced lung injury in a rodent model [9]. To the best of our
knowledge, the protective effects of these drugs against intestinal I/R injury have not been studied before.
2. METHODS
Animal procedures were performed in accordance with the proper use and care of laboratory animals,
approved by the ethics committee of our institution. Experiments were performed on 25 male Wistar rats
weighing 200–250g. Animals were maintained under standard conditions, such as stable room temperature
(24 ± 3◦), a 12h light/12h dark cycle, and access to commercial rat pellets and water ad libitum.B r i e ﬂy,
after pentobarbital sodium anesthesia (Anestesal, Pﬁzer Inc, Mexico) (35mg/kg, i.p), a midline laparotomy
was performed. Animals were placed under heating lamp in order to preserve core body temperature at
(37◦). Ischemia was induced by cross-clamping the superior mesenteric artery for 60min (ischemia), and
removed to allow 60min of reperfusion.
Drug dosages and time of administration were decided based on published literature and on dose-
response trials performed previously in our laboratory (unpublished data). Rats were randomly divided into
ﬁve groups (n = 5): (1) a sham-operated group (Sham), where laparotomy was performed but intestines
were only manipulated but not made ischemic, (2) a control (CTL) group that was subjected to I/R as
described above, (3) a TRI group, that received 100mg/kg of TRI daily, for three days before I/R, (4) a
SAME group, that received 100mg/kg of SAME 1h before surgery, and (5) a DEX group that received
100mg/kg of DEX 1h before surgery. All drugs were administered orally via gavage.
2.1. Tissue Examination
Immediately after concluding the reperfusion period, rats were sacriﬁced by exsanguination from the aorta
and intestinal tissue samples were obtained. The samples were then ﬁxed in 10% neutral buffered formalin
overnight, embedded in parafﬁn, and 4μm-thick sections were stained with hematoxylin and eosin (H/E)
and examined under light microscope by a blinded pathologist. The Chiu score of mucosa injury was used
to evaluate the degree of histological damage in the intestine, as detailed elsewhere [10] .T h es c a l ec o n s i s t s
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TABLE 1: Serum biochemical parameters: AST, LDH, and ALT levels.
Group AST (U/L) LDH (U/L) ALT (U/L)
Sham 145.25 ± 12.1 6080.75 ± 1042.55 52.5 ± 11
CTL 339.2 ± 78.11∗ 10309.40 ± 2240.16∗ 192 ± 82.1∗
SAME 214.25 ± 11.47∗∗ 10,200 ± 1042.4 U/L 74 ± 16.9∗∗
DEX 236.75 ± 16∗∗ 7395 ± 560∗∗ 176 ± 10.45
TRI 166.75 ± 65.9∗∗ 3400 ± 339∗∗ 76 ± 3∗∗
∗
P < 0.05 versus Sham; ∗∗P < 0.05 versus CTL.
of values from of 0 to 5, where 0 normal mucosa; 1 development of subepithelial (Gruenhagen’s) spaces;
2 extension of the subepithelial space with moderate epithelial lifting from the lamina propria; 3 extensive
epithelial lifting with occasional denuded villi tips; 4 denuded villi with exposedlamina propria and dilated
capillaries; 5 disintegration of the lamina propria, hemorrhage, and ulceration.
2.2. Serum Analysis
Blood samples were used to determine serum levels of AST (aspartate-aminotransferase), ALT (alanine-
aminotransferase), and LDH (lactate dehydrogenase) by standard biochemical automated methods, using
commercially available kits and DT6011 and DTSC11 analyzers (System Vitros Chemical, Johnson and
Johnson, USA). AST and LDH plasma levels serve as indirect markers of intestinal injury, while ALT is
more speciﬁc for hepatic injury. Serum concentrations of TNF-alpha were determined using a rat ELISA
kit (PeproTech, Mexico). Lipid peroxidation, expressed as malonaldehyde (MDA) levels, was assessed
by the TBARS method using a commercially available colorimetric assay kit (Cayman chemicals, USA).
Total serum antioxidant capacity (TAC) was assessed using a commercially available colorimetric assay kit
(Cayman chemicals, USA). TAC values are expressed as Trolox Equivalents (TEs).
2.3. Statistical Analysis
SPSS 11.0 statistical software (SPSS Inc. Software, Chicago, Ill, USA) was used to analyze data using
one-way analysis of variance (ANOVA) and with LSD post hoc test (when data were found to be
normally distributed) and Kruskal-Wallis test (when data were not normally distributed) so as to determine
comparison between groups and differences between groups, respectively. All values are expressed as
mean ± SD, and P < 0.05 was considered statistically signiﬁcant.
3. RESULTS
3.1. ALT, AST, and LDH
AST values were signiﬁcantly elevated after I/R in group CTL compared to sham group, and all treatment
groups had AST levels signiﬁcantly lower than CTL group (Table 1). LDH levels in group CTL were sig-
niﬁcantly increased compared to sham group. While groups TRI and DEX showed lower levels of LDH,
levels in SAME group remained comparable to those in CTL group. After I/R, ALT values were increased
in CTL group compared to sham group, but only TRI and SAME were able to reduce ALT elevations
(Table 1).
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FIGURE 1: Chiu score and serum concentrations of TNF-alpha, MDA, and TAC. ∗P < 0.05 versus Sham;
∗∗P < 0.05 versus CTL.
3.2. Morphological Examination
In sham group, Chiu score of mucosal injury was 1 ± 0, indicating negligible injury. In CTL group, severe
mucosal injury was evident after I/R, reaching a Chiu score of 4.2 ± 0.44. In TRI group, there was some
injury but it was signiﬁcantly less than in CTL group (Chiu score: 2.7 ± 0.95, P < 0.05, Figure 1). SAME
group also showed reduced injury compared to CTL group, with Chiu score 2.5 ± 0.57 (P < 0.05). DEX
group showed reduced injury as well, reaching statistical signiﬁcance at 3 ± 1.41 (P < 0.05).
3.3. Serum TNF-Alpha
TNF-alpha levels remained undetectable in sham group. In CTL group, TNF-alpha levels reached 2.26 ±
1ng/mL. TRI group had undetectable TNF-alpha levels by our assay as well, signiﬁcantly lower than in
CTL group (P < 0.05, Figure 1). The TNF-alpha levels in groups SAME and DEX were similar to those in
CTL group (SAME: 4.2 ± 4.9ng/mL; DEX: 0.74 ± 0.88ng/mL).
3.4. MDA and TAC
Sham group had MDA concentrations of 2.56 ± 0.829μM/mL. In CTL group, MDA levels were sig-
niﬁcantlyincreased(7.42± 1.72μM/mL, P <0.05,Figure 1). All treatmentswereeffectivein reducingthe
elevations in serum concentrations of MDA (TRI: 1.59 ± 0.27 U/LμM/mL; SAME: 3.82 ± 0.57μM/mL;
DEX: 4.19 ± 2.12μM/mL, P < 0.05), signiﬁcantly lower to levels in CTL group. Sham group, serum TAC
was 2.749 ± 0.19 TEs. In CTL group, serum antioxidants were signiﬁcantly depleted (2.05 ± 0.36 TEs,
P <0.05).InTRIgroup,serumTACwaspreserved,with levelscomparableto shamgroupandsigniﬁcantly
higherthan in CTL group (2.72 ± 0.11 TEs). In SAME group, serum TAC was actually increasedcompared
to sham group (3.39 ± 0.43 TEs, P < 0.05). However, in DEX group serum TAC showed only a trend
towards higher levels when compared to CTL group (2.58 ± 0.6 TEs, P = 0.07).
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4. DISCUSSION
I/R injury is a potentially devastating condition, associated with many surgical pathologies, and the search
for therapeutic interventions is necessary, given that there is no standard treatment at present time. In this
study, we evaluated the effects of three agents, with different mechanisms of action and clinical use, over
intestinal I/R injury.
TRI was very effective in reducing intestinal I/R injury, as well as the associated TNF-alpha eleva-
tions, oxidative stress markers, and liver injury, as assessed by ALT elevations. TRI is an antiplatelet drug
that inhibits both cyclooxygenase-1 (COX) and 2, decreasing prostaglandin and thromboxane production.
Other COX-2 inhibitors have been also shown to protect the intestine against I/R injury, albeit mildly, while
COX-1 inhibitors have little effects [11]. More studies would be required to show if TRI could be acting
through a COX-2-dependent pathway. Platelet-endothelial interactions in the intestinal microvasculature
play an important pathophysiological role in I/R injury [12]. Additionally, it has been demonstrated that
TRI potently inhibits the transcription factors nuclear factor kappaB (NF-KappaB) and nuclear factor
of activated T cells, responsible for the production of many inﬂammatory cytokines, such as TNF-alpha
[13, 14], also essential in the pathophysiology of I/R injury. In experimental models of cerebral I/R injury,
TRI is effective in reducing tissue injury, through antithrombotic, antioxidant, and antiinﬂammatory effects
[3]. All these mechanisms could be responsible for the results we observed in this study.
Oxidative stress is an important mediator in pathological conditions of I/R injury, and antioxidant
therapy has been widely studied as a protective strategy against this condition [15]. SAME is a precursor
of glutathione, an antioxidant. Glutathione is a powerful cytoprotectant in the intestine, and glutathione
supplementationhas been proposedas a promising therapy for I/R injury [16]. In this study, SAME reduced
intestinal I/R injury, the associated transaminase elevations, lipid peroxidation, and increased serum TAC.
Studies involving I/R of organs such as the brain and liver have previously shown a protective effect of
SAME, attributable to inhibition of lipid peroxidation and increased levels of protective antioxidants [6, 7].
However, SAME has also been effective in reducing inﬂammatory damage in a rodent model of colitis [17],
and in vitro studies indicate that SAME is able to modulate inﬂammatory cytokine production, including
TNF-alpha,in inﬂammatory cells [18]. However,we found no effects of SAME overTNF-alpha serum con-
centrations in our study, despite tissue protection. This dissociation between TNF-alpha production, ox-
idative stress, and tissue injury, after SAME treatment, was described in a recent study, involving a liver I/R
model. Llacunaet al. [19] reported that after SAME treatment, ischemiclivercells hadincreasedexpression
of TNF-alpha genes, despite increased antioxidant gene expression and protection against injury, possibly
because differential effects of SAME over speciﬁc cellular populations. A similar effect could explain our
results.
It is known that NMDA receptors exist in the enteric nervous system and NMDA antagonists are ef-
fective in reducing the functional alterations associatedwith intestinal I/R [20]. In previousstudies,we have
also demonstratedthat ketamine, an NMDA antagonist,could reduceintestinal I/R injury, although whether
this was due to NMDA-related effects, or to ketamine’s antiinﬂammatory activity, remains unclear [10, 19,
21]. In the present study, we found that DEX also had mild protective effects. However, studies suggest
that DEX not only acts through NMDA-inhibition, and other effects, such as calcium channel inhibition,
modulation of c-fos expression, and possibly antiinﬂammatory effects, have been reported [2, 9]. Reduced
levelsofTNF-alphaproduction,hepatoprotection,andinhibitionofcytokinegeneexpressionwere observed
after DEX administration in an endotoxemia model in rats [22], and DEX has also been demonstrated to
inhibit macrophage free radical production in vitro [23]. In the present study, we found no effects of DEX
treatment overeitherTNF-alphalevelsor serumTAC,althoughwe did ﬁndevidenceofreducedlipid perox-
idation. We also found no effects over ALT levels. The precise pathway involved in DEX’s effects over I/R
injury in nonnervous tissue warrants further research.
There are some limitations to this study. The drug doses used are higher than those that are clinically
relevant. Furthermore, we studied acute injury and markers of inﬂammation and oxidative stress, but not
outcome (such as mortality). We also did not study combination treatment, which we assume would be
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effective,sincethedrugsstudiedhavedifferentmechanismsofaction.Theseissuesrequirefurtherinvestiga-
tion.
5. CONCLUSIONS
The search for pleiotropic drugs, capable of modulating the physiopathological mechanisms of I/R injury,
to be used as protective therapies, is an active ﬁeld of research. We have proposed such an application for
three drugs currently in clinical use, each with markedly different mechanisms of action.
CONFLICT OF INTERESTS
The authors declare that they have no conﬂict of interests.
ACKNOWLEDGMENTS
The authors would like to thank the staff at their labs for invaluable assistance and MVZ Jose Luis Vazquez
Juarez for providing laboratory animals and ensuring their care.
REFERENCES
[1] I. H. Mallick, W. Yang, M. C. Winslet, and A. M. Seifalian, “Ischemia-reperfusion injury of the intestine and
protective strategies against injury,” Digestive Diseases and Sciences, vol. 49, no. 9, pp. 1359–1377,2004.
[2] S. E. Kong, L. R. Blennerhassett, K. A. Heel, R. D. Mccauley, and J. C. Hall, “Ischaemia-reperfusion injury to
the intestine,” Australian and New Zealand Journal of Surgery, vol. 68, no. 8, pp. 554–561, 1998.
[3] J. A. Gonz´ alez-Correa and J. P. de la Cruz, “Triﬂusal: an antiplatelet drug with a neuroprotective effect?”
Cardiovascular Drug Reviews, vol. 24, no. 1, pp. 11–24, 2006.
[4] S. N. Whitehead, N. A. Bayona, G. Cheng, G. V. Allen, V. C. Hachinski, and D. F. Cechetto, “Effects of triﬂusal
and aspirin in a rat model of cerebral ischemia,” Stroke, vol. 38, no. 2, pp. 381–387, 2007.
[5] C. S. Lieber,“S-adenosyl-L-methionine:its role in the treatmentof liver disorders,”American JournalofClinical
Nutrition, vol. 76, no. 5, pp. 1183S–1187S, 2002.
[6] M. A. Villalobos, J. P. de la Cruz, M. A. Cuerda, P. Ortiz, J. M. Smith-Agreda, and F. S. de la Cuesta, “Effect of
S-adenosyl-L-methionineon rat brain oxidative stress damage in a combined model of permanentfocal ischemia
and global ischemia-reperfusion,”Brain Research, vol. 883, no. 1, pp. 31–40, 2000.
[7] Y. B. Lee and S. M. Lee, “Effect of S-adenosylmethionine on hepatic injury from sequential cold and warm
ischemia,” Archives of Pharmacal Research, vol. 23, no. 5, pp. 495–500, 2000.
[8] P. M. Bokesch, J. E. Marchand, C. S. Connelly, W. H. Wurm, and R. M. Kream, “Dextromethorphan inhibits
ischemia-induced c-fos expression and delayed neuronal death in hippocampal neurons,” Anesthesiology,v o l .
81, no. 2, pp. 470–477, 1994.
[9] R. Ben-Abraham, M. Guttman, R. Flaishon, N. Marouani, D. Niv, and A. A. Weinbroum, “Mesenteric artery
clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextrome-
thorphan,”Lung, vol. 184, no. 6, pp. 309–317, 2006.
[10] C. R. C´ amara, F. J. Guzm´ an, E. A. Barrera et al., “Ketamine anesthesia reduces intestinal ischemia/reperfusion
injury in rats,” World Journal of Gastroenterology, vol. 14, no. 33, pp. 5192–5196,2008.
[11] T. V. Arumugam,N. Arnold,L. M. Proctoret al., “Comparativeprotectionagainstrat intestinalreperfusioninjury
by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist,” British
Journal of Pharmacology, vol. 140, no. 1, pp. 71–80, 2003.
[12] S. Massberg, G. Enders, R. Leiderer et al., “Platelet-endothelialcell interactionsduring ischemia/reperfusion:the
role of P-selectin,” Blood, vol. 92, no. 2, pp. 507–515, 1998.
[13] Y. Bay´ on, A. Alonso, and M. S. Crespo, “4-Triﬂuoromethyl derivatives of salicylate, triﬂusal and its main
metabolite2-hydroxy-4-triﬂuoromethylbenzoicacid,arepotentinhibitorsofnuclearfactorκBactivation,”British
Journal of Pharmacology, vol. 126, no. 6, pp. 1359–1366, 1999.
1891TheScientiﬁcWorldJOURNAL (2011) 11, 1886–1892
[14] M. Aceves, A. Due˜ nas, C. G´ omez, E. San Vicente, M. S. Crespo, and C. Garc´ ıa-Rodr´ ıguez, “A new pharmaco-
logical effect of salicylates: inhibition of NFAT-dependent transcription,” Journal of Immunology, vol. 173, no.
9, pp. 5721–5729,2004.
[15] A. Ma, S. Qi, and H. Chen, “Antioxidant therapy for prevention of inﬂammation, ischemic reperfusion injuries
and allograft rejection,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 6, no. 1, pp.
20–43, 2008.
[16] H. Jefferies, J. Bot, J. Coster, A. Khalil, J. C. Hall, and R. D. McCauley, “The role of glutathione in intestinal
dysfunction,”Journal of Investigative Surgery, vol. 16, no. 6, pp. 315–323, 2003.
[17] H. S. Oz, T. S. Chen, C. J. McClain, and W. J. S. de Villiers, “Antioxidants as novel therapy in a murine model
of colitis,” Journal of Nutritional Biochemistry, vol. 16, no. 5, pp. 297–304, 2005.
[18] J. Yu, S. Sauter, and A. Parlesak, “Suppression of TNF-α production by S-adenosylmethionine in human
mononuclearleukocytesis not mediated by polyamines,”Biological Chemistry, vol. 387, no. 12, pp. 1619–1627,
2006.
[19] L. Llacuna, M. Mar´ ı, J. M. Lluis, C. Garc´ ıa-Ruiz, J. C. Fern´ andez-Checa, and A. Morales, “Reactive oxygen
species mediate liver injury through parenchymal nuclear factor-κB inactivation in prolonged ischemia/re-
perfusion,” American Journal of Pathology, vol. 174, no. 5, pp. 1776–1785,2009.
[20] C. R. C´ amara-Lemarroy, F. J. Guzm´ an-de la Garza, G. Alarc´ on-Galv´ an, P. Cordero-P´ erez, and N. E. Fern´ andez-
Garza, “The effects of NMDA receptor antagonists over intestinal ischemia/reperfusioninjury in rats,” European
Journal of Pharmacology, vol. 621, no. 1–3, pp. 78–85, 2009.
[21] F. J. G. Garza, C. R. C´ amara-Lemarroy, R. G. Ballesteros-Elizondo, G. Alarc´ on-Galv´ an, P. Cordero-P´ erez, and
N. E. Fern´ andez-Garza, “Ketamine reduces intestinal injury and inﬂammatory cell inﬁltration after ischemia/re-
perfusion in rats,” Surgery Today, vol. 40, no. 11, pp. 1055–1062,2010.
[22] G. Li, Y. Liu, N. S. Tzeng et al., “Protective effect of dextromethorphan against endotoxic shock in mice,”
Biochemical Pharmacology, vol. 69, no. 2, pp. 233–240, 2005.
[23] S. L. Liu, Y. H. Li, G. Y. Shi et al., “Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and
neointima formation in mice,” Cardiovascular Research, vol. 82, no. 1, pp. 161–169, 2009.
This article should be cited as follows:
Carlos R. C´ amara-Lemarroy, Francisco J. Guzm´ an-de la Garza, Paula Cordero-P´ erez, Gabriela Alarc´ on-
Galv´ an,Liliana Torres-Gonzalez,LindaE. Mu˜ noz-Espinosa,andNancyE.Fern´ andez-Garza,“Comparative
Effects of Triﬂusal, S-Adenosylmethionine, and Dextromethorphan over Intestinal Ischemia/Reperfusion
Injury,” TheScientiﬁcWorldJOURNAL,vol. 11, pp. 1886–1892, 2011.
1892